Amanote Research

Amanote Research

    RegisterSign In

Beyond PD-1 Immunotherapy in Malignant Melanoma

Dermatology and Therapy - Germany
doi 10.1007/s13555-019-0292-3
Full Text
Open PDF
Abstract

Available in full text

Categories
Dermatology
Date

March 29, 2019

Authors
Dominika KwiatkowskaPiotr KluskaAdam Reich
Publisher

Springer Science and Business Media LLC


Related search

Active Immunotherapy in Malignant Melanoma.

BMJ
1978English

OS7 - 145 Combination Immunotherapy for Glioma: Beyond PD 1 Inhibition

Canadian Journal of Neurological Sciences
MedicineNeurology
2016English

Circulating Tumour DNA for Monitoring Treatment Response to Anti-Pd-1 Immunotherapy in Melanoma Patients

Acta Dermato-Venereologica
DermatologyMedicine
2017English

CTLA4 Methylation Predicts Response to Anti–PD-1 and Anti–CTLA-4 Immunotherapy in Melanoma Patients

JCI insight
Medicine
2018English

820 M6A mRNA Demethylase FTO Regulates Tumorigenicity and Response to Anti-Pd-1 Immunotherapy in Melanoma

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

Tumor Immunotherapy Directed at PD-1

New England Journal of Medicine
Medicine
2012English

Oral Lichen Planus Developing After PD-1 Inhibitor Therapy in Two Patients With Malignant Melanoma

Journal of Clinical and Investigative Dermatology
2019English

What Can We Learn Regarding Immunotherapy From Malignant Melanoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

PAK4 Inhibition Improves PD-1 Blockade Immunotherapy

Nature Cancer
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy